licensor dependence

Depending on rights licensed from others for key products or content.

Exposure · 6 companies

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

  • APMD Apnimed, Inc.

    Exposed“Oxnimbi depends on third-party intellectual-property rights, particularly the BWH License, with diligence, milestone, and royalty obligations; breach or loss of licensed rights could impair or prevent commercialization.”

    Latest 424B4final IPO prospectusBankruptcy / going concernAccounting issueCEO/CFO change ·

    Develops Oxnimbi, a once-nightly sleep apnea pill; $192M all-primary raise funds regulatory work and launch if approved.

  • INVA Innoviva, Inc.

    Exposed“GSK controls development, regulatory, manufacturing, pricing and commercialization decisions, leaving INVA with limited influence over sales effort, market access, product prioritization or resource allocation.”

    Latest 10-QQ3 FY2026Positive ·

    XACDURO and GIAPREZA lift U.S. hospital sales; Armata markdowns overwhelm stronger operating earnings

    • Revenue$106.1MYoY −1.6%
    • Net income−$73.9Mvs $89.9M year ago
  • NFLX Netflix, Inc.

    Exposed“Our ability to provide our members with content they can watch depends on studios, content providers and other rights holders licensing rights, including distribution rights, to such content and certain related elements thereof, such as the public performance of music contained within the content we distribute.”

    Latest 10-QQ3 FY2026Positive ·

    Membership growth, pricing and ads lift revenue; margin expansion benefits from a prior-year Brazil tax assessment.

    • Revenue$12.9BYoY +11.8%
    • Net income$3.7BYoY +43.9%
  • SDGR Schrödinger, Inc.

    Exposed“Litigation, third-party infringement claims, ownership disputes, or loss of key Columbia University-licensed technology could require costly licenses, redesign, or cessation of affected work.”

    Latest 10-QQ3 FY2026 ·

    Structure Therapeutics milestone drove revenue growth; hosted migration obscured stronger software contracting.

    • Revenue$64.5MYoY +18.7%
    • Net income−$37.7MYoY −15.0%
  • VOGX Vogenx, Inc.

    Exposed“Mizagliflozin depends substantially on an exclusive, royalty-bearing global license from Kissei, excluding Korea, Taiwan, and Japan.”

    Latest 424B4final IPO prospectusPositiveBankruptcy / going concernRestatementAccounting issue ·

    Developing oral mizagliflozin for post-bariatric hypoglycemia; $81.3M gross raise funds Phase 2 trials.

  • WWB WINDWARD BIO GROUP AG

    Exposed“WWB relies on data, development work, and rights from licensors Kelun and HBM for WIN378 and Qyuns for WIN027.”

    Latest 424B4final IPO prospectusPositivePre-revenue ·

    Develops long-acting antibodies for asthma and other inflammatory diseases; $175M raise funds trials led by WIN378’s potential twice-yearly dosing

Feedback